Click here to


Are you sure ?

Yes, do it No, cancel

Imaging Biomarkers in Radiation Oncology and Beyond: Development, Evaluation and Clinical Translation

J Waterton1*, N Tyagi2*, T Yamamoto3*, I El Naqa4*, (1) University Of Manchester, Manchester, GB, (2) Memorial Sloan-Kettering Cancer Center, New York, NY, (3) UC Davis School of Medicine, Sacramento, CA, (4) University of Michigan, Ann Arbor, MI


(Tuesday, 7/14/2020) 11:30 AM - 12:30 PM [Eastern Time (GMT-4)]

Room: Track 5

Imaging biomarkers play a critical role in the routine care of cancer patients. Despite the large number of published imaging biomarkers, many of which have great potential, very few are in widespread clinical use. For successful clinical translation, all biomarkers must cross two translational gaps: to first become robust clinical research tools; and then to be integrated into routine clinical care. This goal can only be achieved through parallel technical validation of the “assay” itself, validation of the biological and clinical interpretation, and evaluation of clinical utility and cost-effectiveness. Several multistakeholder groups, including the Quantitative Imaging Biomarkers Alliance (QIBA) and the international consensus statement (“Imaging Biomarker Roadmap for Cancer Studies”), have provided recommendations to facilitate translation of imaging biomarkers into clinical practice.

This symposium seeks to bring together experts to promote interdisciplinary collaboration to accelerate the development and evaluation of imaging biomarkers for radiation oncology and the integration of validated biomarkers into clinical practice. The first speaker, Dr. Waterton who is the senior author on the consensus statement mentioned above, will provide an overview of the Imaging Biomarker Roadmap for Cancer Studies. Then, two speakers, Dr. Tyagi and Dr. Yamamoto, will describe examples of tumor and normal tissue imaging biomarkers, respectively, at various stages of development and evaluation. The last speaker, Dr. El Naqa, will discuss the future of advanced quantitative imaging biomarkers (radiomics) in radiotherapy and immunotherapy.

Learning Objectives:
1. Understand the key steps for technical standardization, technical validation, biological/clinical validation, and evaluation of clinical utility and cost-effectiveness to accelerate the successful clinical translation of imaging biomarkers.
2. Recognize the strengths and limitations of existing imaging biomarkers used in the routine care of cancer patients and emerging imaging biomarkers at various stages of development.
3. Promote collaboration among imaging and therapy physicists in the standardization, development, evaluation and clinical translation of quantitative imaging biomarkers in radiation oncology and beyond.

Funding Support, Disclosures, and Conflict of Interest: J Waterton: Director; Bioxydyn Ltd. Research Grant; IMI (115151, 116106). N Tyagi: Research Agreement; Philips. Research Agreement; Elekta Healthcare. Research Grant; MSKCC IMRAS seed grant. T Yamamoto: Research Agreement; Philips. Research Grant; UC Davis. I El Naqa: Scientific Advisory; Endectra LLC. Scientific Advisory; Resero AI. Research Grant; NIH.



Not Applicable / None Entered.


Not Applicable / None Entered.

Contact Email